Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMY729C)

Drug Name

NK314 Drug Info

Synonyms

208237-49-4; 1-hydroxy-2-methoxy-11a,13,14,15-tetrahydro-6aH-[1,3]dioxolo[4',5':4,5]benzo[1,2-c]pyrrolo[1,2-f]phenanthridin-12-ium chloride

Indication

Disease Entry	ICD 11	Status	REF
T-cell leukaemia	2A90	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting DNA topoisomerase II alpha (TOP2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PK1	DMKEV7N	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
Camsirubicin	DMEZLFT	Soft tissue sarcoma	2B57	Phase 2	[4]
Annamycin	DMDHJNV	Acute myeloid leukaemia	2A60	Phase 1/2	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II alpha (TOP2A)	TTCGY2K	TOP2A_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase. Blood. 2011 Mar 31;117(13):3575-84.
2	NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008 Aug 29;283(35):23711-20.
3	Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009 Jun;34(6):1629-36.
4	Clinical pipeline report, company report or official report of Monopar Therapeutics.
5	Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Arch Immunol Ther Exp (Warsz). May-Jun 2007;55(3):193-8.